"Pharmaceutical Companies Scramble to Meet Surging Demand for Weight Loss Medications"

Demand for weight loss drugs, such as Ozempic and Mounjaro, has skyrocketed, causing a shortage in supply. Novo Nordisk and Eli Lilly, the makers of these drugs, are struggling to meet the increasing demand. The FDA's potential approval of Mounjaro for obesity treatment may further strain the supply chain. Both companies are investing billions of dollars to expand production capacity, but it will take time to catch up. The drugs, commonly used off-label for weight loss, come with side effects and high costs. Insurance coverage and supply issues have led to difficult prescribing decisions for clinicians. The shortage is particularly challenging for patients in wealthier areas who can afford to pay out of pocket. Despite the challenges, the market for obesity drugs is expected to generate significant revenue in the coming years.